Elective switching from infliximab to adalimumab in stable crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 761-766

  Hoentjen, Frank ^a,b   Haarhuis, Bertram J T ^b   Drenth, Joost P H ^b   De Jong, Dirk J ^a,b  

^a Inflammatory Bowel Disease Center   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Azathioprine; Crohn's disease; Infliximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; INFLIXIMAB; PREDNISONE;

ABSCESS DRAINAGE; ADULT; AGED; ARTICLE; CAMPYLOBACTER ENTERITIS; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HARVEY BRADSHAW INDEX; HEADACHE; HUMAN; INFUSION RELATED REACTION; INJECTION SITE PAIN; LEUKOCYTE COUNT; MALE; MITRAL VALVE REPLACEMENT; MOOD CHANGE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84876359766     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182802ae1     Document Type: Article

References (17)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
2. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
3. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499.
4. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.
5. Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an antitumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18:1523-1530.
6. Sussman DA, Kubiliun N, Mulani PM, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis. 2012;18:2043-2055.
7. Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012;61:229-234.
8. Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther. 2011;34: 1-10.
9. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
10. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106:674-684.
11. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009;104: 1170-1179.
12. Loftus EV Jr, Pan X, Zurawski P, et al. Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States. J Crohns Colitis. 2011;5:550-554.
13. Pocock SJ. When (not) to stop a clinical trial for benefit. JAMA. 2005;294: 2228-2230.
14. Su HC, Sammel MD. Interim analysis in clinical trials. Fertil Steril. 2012; 97:e9- e10; author reply.
15. Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912-1921.
16. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275.
17. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70 e65; quiz e31.